Model‐Informed Optimal Dosing of Anti‐ CD47 Antibody Using Target‐Mediated Drug Disposition Model
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70321 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Seongmee Jeong und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: CD47 Antigen, Neoplasms, Models, Biological, Antibodies, Monoclonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chungnam National University, Institute of Information & Communications Technology Planning Evaluation (IITP), National Research Foundation of Korea (NRF), Korea Environmental Industry & Technology Institute (KEITI).
Abstract (Originalsprache)
IMC‐002, an anti‐cluster of differentiation 47 (CD47) antibody, was developed as a fully human immunoglobulin (Ig) G4 monoclonal antibody targeting CD47. IMC‐002 blocks CD47–signal regulatory protein alpha (SIRPα) interactions, increasing the phagocytosis of cancer cells by macrophages. This study established a target‐mediated drug disposition (TMDD) pharmacokinetics (PK) model for IMC‐002 to explain the characteristics of the neonatal Fc receptor (FcRn) of IgG based on phase I a trial data to perform model‐informed optimal dosing for a phase I b study. The PK data were obtained from a phase I a dose escalation study on 12 patients with advanced solid tumors. Each patient received multiple doses (5, 10, 20, or 30 mg/kg) via intravenous infusion over 3 h every 2 weeks. The IMC‐002 PK data were analyzed using NONMEM software (version 7.5) using the first‐order conditional estimation method with interaction (FOCEI). The semi‐mechanistic TMDD model explained the nonlinear PK properties of IMC‐002, including FcRn recirculation. Weight, sex, and age were investigated as covariates using stepwise covariate testing. No statistical covariates were identified. Simulations were performed to determine the optimal dosing regimen for patients with solid tumors that extend the administration period and maintain the mean concentrations above the minimum effective concentration (MEC). The ideal regimen of 20 mg/kg every 3 weeks ensured that the mean plasma concentration remained above the MEC throughout the dosing interval. Our study developed a robust TMDD PK model for IMC‐002, which provides the rationale for a dose regimen in a phase 1 b study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
- ImmuneOncia Therapeutics, Inc., Seoul, Republic of Korea.
- Bio-AI Convergence Research Center, Chungnam National University, Daejeon, Republic of Korea.
- Convergence Research Center (CRC), Chungnam National University, Daejeon, Republic of Korea.
ORCID-Profile: Seongmee Jeong, Hwi-Yeol Yun, Jung-Woo Chae, Soyoung Lee
Förderung
- Chungnam National University, Institute of Information & Communications Technology Planning Evaluation (IITP)
- National Research Foundation of Korea (NRF)
- Korea Environmental Industry & Technology Institute (KEITI)
- Ministry of Health & Welfare and Ministry of Science and ICT
- Korea Institute of Toxicology (KIT)
- Korea Health Industry Development Institute (KHIDI)
- Korea Institute for Advancement of Technology (KIAT)
- Chungnam National University
Zitieren
APA
Jeong, S., Lee, S. Y., Kim, S. H., Kim, H. T., Yun, H. Y., Chae, J. W., & Lee, S. (2025). Model‐Informed Optimal Dosing of Anti‐ CD47 Antibody Using Target‐Mediated Drug Disposition Model. Clinical and Translational Science. https://doi.org/10.1111/cts.70321
Vancouver
Jeong S, Lee SY, Kim SH, Kim HT, Yun HY, Chae JW, et al. Model‐Informed Optimal Dosing of Anti‐ CD47 Antibody Using Target‐Mediated Drug Disposition Model. Clinical and Translational Science. 2025. doi:10.1111/cts.70321
BibTeX
@article{Jeong2025,
author = {Jeong, Seongmee and Lee, Sung Young and Kim, Sung Ho and Kim, Heung Tae and Yun, Hwi-Yeol and Chae, Jung-Woo and Lee, Soyoung},
title = {Model‐Informed Optimal Dosing of Anti‐ CD47 Antibody Using Target‐Mediated Drug Disposition Model},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70321}
}
EUVIMED